- Home
- PSF vs AMRN Comparison
PSF vs AMRN Comparison
Compare PSF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$13.46
Company Overview
Basic Information| Metric | PSF | AMRN |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | PSF | AMRN |
|---|---|---|
| Price | $20.37 | $13.46 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 25.0K | ★ 94.7K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $7.08 |
| 52 Week High | $20.19 | $20.90 |
Technical Indicators
Market Signals| Indicator | PSF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 37.30 |
| Support Level | $20.22 | $13.48 |
| Resistance Level | $20.39 | $14.33 |
| Average True Range (ATR) | 0.12 | 0.64 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 96.67 | 26.57 |
Price Performance
Historical Comparison PSF
AMRN
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.